222 BERKELEY STREET, BOSTON, MA
Reports First Quarter 2026 Financial Results and Business Update
Announces Changes to Board of Directors
Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Investor Presentation
Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Q1
FY 2025
Q3
Q2
FY 2023
Q2 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership